"Mifepristone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.
| Descriptor ID |
D015735
|
| MeSH Number(s) |
D04.210.500.365.415.580
|
| Concept/Terms |
R-38486- R-38486
- R 38486
- RU-486
- RU 486
- RU486
- R38486
- RU-38486
- RU 38486
- RU38486
|
Below are MeSH descriptors whose meaning is more general than "Mifepristone".
Below are MeSH descriptors whose meaning is more specific than "Mifepristone".
This graph shows the total number of publications written about "Mifepristone" by people in this website by year, and whether "Mifepristone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 2 | 3 |
| 1998 | 1 | 2 | 3 |
| 1999 | 0 | 6 | 6 |
| 2000 | 2 | 2 | 4 |
| 2001 | 1 | 3 | 4 |
| 2002 | 2 | 6 | 8 |
| 2003 | 0 | 8 | 8 |
| 2004 | 2 | 4 | 6 |
| 2005 | 0 | 4 | 4 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 3 | 3 |
| 2009 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mifepristone" by people in Profiles.
-
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun. 2023 12 13; 3(12):2531-2543.
-
Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Sci Adv. 2023 07 21; 9(29):eadf7195.
-
Medication abortion with misoprostol-only: A sample protocol. Contraception. 2023 05; 121:109998.
-
Visualization of preimplantation uterine fluid absorption in mice using Alexa Fluor? 488 Hydrazide?. Biol Reprod. 2023 02 13; 108(2):204-217.
-
Targeting progesterone signaling prevents metastatic ovarian cancer. Proc Natl Acad Sci U S A. 2020 12 15; 117(50):31993-32004.
-
Medication abortion use among low-income and rural Texans before and during state-imposed restrictions and after FDA-updated labeling. Am J Obstet Gynecol. 2020 08; 223(2):236.e1-236.e8.
-
Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma. Clin Cancer Res. 2020 03 01; 26(5):1175-1184.
-
Growth regulation by estrogen in breast cancer 1 (GREB1) is a novel progesterone-responsive gene required for human endometrial stromal decidualization. Mol Hum Reprod. 2017 09 01; 23(9):646-653.
-
An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review. Clin Obstet Gynecol. 2016 03; 59(1):30-52.
-
Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK. Mol Endocrinol. 2016 Feb; 30(2):158-72.